(Total Views: 498)
Posted On: 01/03/2020 9:14:53 AM
Post# of 9144
Fred,
Study should go well as long as the development goes well. The time estimate of 2021 for marketing appears to have been well thought out. Publication is essential to provide information to the profession on the effectiveness and steps for use in a clinical environment. I can see a home-use dimension for the pretest also. That impact could be immense. Having the package state “FDA Approved. In patient studies the following results....” is far better than “not FDA approved, use at your own risk”
Scott
Study should go well as long as the development goes well. The time estimate of 2021 for marketing appears to have been well thought out. Publication is essential to provide information to the profession on the effectiveness and steps for use in a clinical environment. I can see a home-use dimension for the pretest also. That impact could be immense. Having the package state “FDA Approved. In patient studies the following results....” is far better than “not FDA approved, use at your own risk”
Scott
(3)
(1)
